Medium Dose of Cytarabine and Mitoxantrone

Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia

NCT04415008 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

NCT06990321 ·Status: RECRUITING ·Phase: PHASE3

Haplo-SCT vs ASCT With or Without Decitabine in AML CR1

NCT02059720 ·Status: UNKNOWN ·Phase: PHASE3

AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy

NCT02024308 ·Status: UNKNOWN ·Phase: PHASE4

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

NCT01929408 ·Status: COMPLETED

Mitoxantrone Hydrochloride Liposome Combined With BU/Cy Were Used as a Conditioning Regimen for Patients With Intermediate/Adverse Risk or Persistently Positive MRD AML

NCT06758726 ·Status: NOT_YET_RECRUITING ·Phase: NA

Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

NCT06744504 ·Status: RECRUITING ·Phase: PHASE3

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT06345365 ·Status: RECRUITING ·Phase: PHASE3

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients

NCT06379360 ·Status: RECRUITING ·Phase: PHASE2

Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML

NCT03620955 ·Status: UNKNOWN

Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years

NCT02432872 ·Status: UNKNOWN ·Phase: NA

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

NCT00047021 ·Status: COMPLETED ·Phase: PHASE2

Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

NCT00278213 ·Status: COMPLETED ·Phase: PHASE2

Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+

NCT02936089 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

NCT05061147 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML

NCT06741722 ·Status: RECRUITING ·Phase: PHASE2

Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy

NCT06066242 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

NCT05382390 ·Status: RECRUITING ·Phase: PHASE3

The Efficacy of Allo-HSCT in ND HR-CBF-AML

NCT06458244 ·Status: RECRUITING

Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia

NCT01839240 ·Status: COMPLETED ·Phase: PHASE1

Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML

NCT04248595 ·Status: UNKNOWN ·Phase: PHASE2

Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS

NCT06046313 ·Status: RECRUITING ·Phase: PHASE2

Influence of Molecular Abnormalities on Response of VAH vs. VEN+HMA in RR-AML

NCT05456048 ·Status: COMPLETED

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

NCT06744556 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT

NCT02850822 ·Status: UNKNOWN